StonkScan
OverviewRevenueFinancialsValuationOutlookOwnership
Price
Performance · vs S&P 500
Company
Pfizer Inc.
NYSE · USD
Large cap
1.18× peer median
0.44× peer median
72% less volatile
Claude reads this page's data and writes up Pfizer Inc.'s financials, valuation and analyst coverage: built only from the figures here, with nothing pulled in from elsewhere.
Generated by an AI model from the data on this page. It can be wrong, and it isn't investment advice or a recommendation to buy or sell anything. Check every figure against the sections themselves before you rely on it.
$51.5B of net debt against $11.7B of annual operating cash flow.
Liquidity · FY25
$81.3B in FY21 to $62.6B in FY25, with the latest year down 1.6%.
Growth · FY25
$42.9B of current assets against $37.0B due within a year.
Liquidity · FY25
25.6% in FY21 to 24.7% in FY25.
Profitability · FY25
Free cash flow of $9.1B covers the business without outside capital, on $13.6B of cash and short-term investments.
Liquidity · FY25
$62.6B of revenue against $47.1B of operating costs, leaving $15.5B.
Profitability · FY25
$79.6B of free cash flow against $71.4B of net income across 5 fiscal years.
Quality · FY25
Revenue came in above consensus by 3.5% on average over the last four reports.
Quality · Aug '26
Investors won't start seeing the fruits of Pfizer's current efforts for several more years. A handful of its top-selling drugs will be losing their patent protection in the meantime.
Medicus Pharma Ltd. (NASDAQ:MDCX) secured on Wednesday an exclusive, sublicensable global license from Pfizer Inc. (NYSE:PFE) to develop, manufacture, and commercialize PF-08046031 (CD228V), an early clinical-stage antibody-drug conjugate targeting melanotransferrin.
Pfizer (PFE) reported earnings 30 days ago. What's next for the stock?
PFE's pipeline is taking center stage as berobenatide and next-generation oncology drugs aim to drive growth from 2028 and beyond.
Pfizer's financial results aren't great, and the company will face important patent cliffs relatively soon. However, the company may have a deep enough pipeline to supercharge top-line growth.
If you're looking to invest $1,000 in a dividend stock, look to the pharmaceutical sector.
Average month-end to month-end move for PFEin each calendar month. Point at a bar for that month's spread: past seasonality is a tendency in a small sample, not a forecast.
−$1.0B vs FY24
FY24 → FY25
FY21 → FY25, annualized
−0.2% vs the four before
Q2 FY26 · +2.6% YoY
Share of the latest fiscal year, largest first. The line is the segment across every fiscal year we have: hover it to read one.
What each segment added to or took off the top line in dollars: ranked by the size of the move, not its percentage.
−1.6% YoY
+4.5 pp YoY
−1.2 pp YoY
−3.1% YoY
−0.2 pp YoY
−4.2% YoY
−7.7% YoY
−$7.7B YoY
| $ billions | FY25 | FY24 | FY23 | FY22 | FY21 |
|---|---|---|---|---|---|
| Cash & equivalents | 1.1 | 1.0 | 2.9 | 0.4 | 1.9 |
| Short-term investments | 12.5 | 19.4 | 9.8 | 22.3 | 29.1 |
| Receivables | 15.8 | 14.8 | 15.5 | 14.5 | 15.7 |
| $ billions | FY25 | FY24 | FY23 | FY22 | FY21 |
|---|---|---|---|---|---|
| Operating cash flow | 11.7 | 12.7 | 8.7 | 29.3 | 32.6 |
| Capital expenditure | −2.6 | −2.9 | −3.9 | −3.2 | −2.7 |
| Free cash flow | 9.1 | 9.8 | 4.8 |
P/E vs EPS growth · below the channel = cheaper for its growth
P/S vs revenue growth · below the channel = cheaper for its growth
| Ticker | P/E | Fwd P/E | PEG | P/S | Fwd P/S | PSG | EPS gr | Rev gr |
|---|---|---|---|---|---|---|---|---|
| PFE | 38.1 | 9.7 | 0.43 | 2.6 | 2.6 | - | 22% | -4% |
| MRK | 120.9 | 55.4 | 4.26 | 5.7 | 5.6 | 1.22 | 13% | 5% |
| AMGN | 27.4 | 19.2 | 0.89 | 6.3 | 6.2 | 1.48 | 22% | 4% |
| NVO | 11.4 | 2.1 | 2.10 | 4.0 | 0.7 | 0.44 | 1% | 2% |
| GILD | -58.2 | -327.9 | -20.49 | 6.2 | 6.1 | 1.15 | 16% | 5% |
| DHR | 37.3 | 24.8 | 0.95 | 5.9 | 5.6 | 0.78 | 26% | 7% |
Dots = reported EPS vs consensus · gap = surprise · dashed = estimate ($)
Solid = reported · dashed = forward consensus · shaded = analyst low–high ($B)
Rows: discount rate (r) · Columns: terminal growth (g∞) · cell = fair value, shaded by up/downside vs 29.
Last 12M · $91M bought · $45M sold · net +$46M
| Inventory |
|---|
| 10.7 |
| 10.9 |
| 10.2 |
| 9.0 |
| 9.1 |
| Total current assets | 42.9 | 50.4 | 43.3 | 51.3 | 59.7 |
|---|
| Property, plant & equipment | 21.5 | 18.4 | 18.9 | 16.3 | 14.9 |
|---|
| Long-term investments | 1.7 | 2.2 | 15.4 | 15.1 | 21.5 |
|---|
| Other non-current assets | 142.0 | 142.4 | 148.9 | 114.6 | 85.4 |
|---|
| Total assets | 208.2 | 213.4 | 226.5 | 197.2 | 181.5 |
|---|
| Accounts payable | 5.2 | 5.6 | 6.7 | 6.8 | 5.6 |
|---|
| Short-term debt | 3.5 | 6.9 | 10.3 | 2.9 | 2.2 |
|---|
| Total current liabilities | 37.0 | 43.0 | 47.8 | 42.1 | 42.7 |
|---|
| Long-term debt | 61.6 | 57.4 | 60.5 | 31.9 | 34.8 |
|---|
| Total liabilities | 121.4 | 124.9 | 137.2 | 101.3 | 104.0 |
|---|
| Shareholders’ equity | 86.5 | 88.2 | 89.0 | 95.7 | 77.2 |
|---|
Fiscal year · latest five reported years
| 26.0 |
| 29.9 |
| Investing cash flow | −1.4 | 2.7 | −32.3 | −15.8 | −22.5 |
|---|
| Dividends paid | −9.8 | −9.5 | −9.2 | −9.0 | −8.7 |
|---|
| Share buybacks | 0.0 | 0.0 | 0.0 | −2.0 | 0.0 |
|---|
| Net debt issued / (repaid) | −0.1 | −7.2 | 35.9 | −3.5 | −1.1 |
|---|
| Financing cash flow | −10.3 | −17.1 | 26.1 | −14.8 | −9.8 |
|---|
| Net change in cash | 0.1 | −1.8 | 2.4 | −1.5 | 0.2 |
|---|
Fiscal year · outflows shown negative